Analyst firms · Barclays · MEDP
Barclays MEDP price target and rating history
Medpace Holdings Inc. (MEDP) · Health Care
Barclays rates Medpace Holdings Inc. (MEDP) Equal Weight with a $500 price target, as of its latest action on Mar 6, 2026. It has published 3 rating actions on MEDP since June 2025, including 1 upgrade and 1 downgrade. Across 7 firms with a MEDP price target in the last 12 months, the median target is $522. Barclays's $500 is 4% below that.
- Current rating
- Equal Weight
- Price target
- $500
- Median target, all firms
- $522
- Actions on MEDP
- 3
Barclays price target on MEDP
Every Barclays rating on MEDP
- Mar 6, 2026
- Oct 2, 2025
- Jun 24, 2025
How other firms rate MEDP
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $673 | Sep 30, 2026 |
| Robert W. Baird | Neutral | $547 | Jul 8, 2026 |
| Jefferies | Hold | $515 | Jul 7, 2026 |
| Barclays | Equal Weight | $500 | Mar 6, 2026 |
| RBC Capital Markets | Outperform | $522 | Mar 3, 2026 |
| TD Cowen | Hold | $419 | Feb 18, 2026 |
| BMO Capital Markets | Market Perform | $600 | Nov 13, 2025 |
Questions about Barclays and MEDP
- What is Barclays's price target for MEDP?
- Barclays's latest stated price target for Medpace Holdings Inc. (MEDP) is $500, from its action on Mar 6, 2026.
- What is Barclays's rating on MEDP?
- Barclays rates MEDP Equal Weight, a neutral rating, as of Mar 6, 2026.
- When did Barclays last change its view on MEDP?
- On Mar 6, 2026, Barclays upgrades to Equal Weight from Underweight, price target $500.
- How does Barclays's MEDP target compare with other analysts?
- Across 7 firms with a MEDP price target in the last 12 months, the median target is $522. Barclays's $500 is 4% below that.
More MEDP rating histories
All Barclays ratingsMEDP news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.